Abstract
ABSTRACT Nonalcoholic fatty liver disease (NAFLD) is known as the accumulation of triglycerides in liver without alcohol consumption. Liraglutide is an analogue of glucagon-like peptide-1 hormone (GLP-1). It is known to decrease blood glucose, body weight and food intake. The present study is designed to study the effect of liraglutide on the experimental model of NAFLD. Thirty-six adult male albino rats were divided into three groups. Group I was the control group. Group II (FLD group) received a high-fat fructose diet for 16 weeks. Group III (FLD + Lira) received high-fat fructose diet daily for 16 weeks and were injected with Liraglutide intraperitoneally at a dose of 0.6 mg/kg/day in the last 4 weeks. Liver sections were prepared for histological, immunohistochemical and Western blot study of alpha smooth muscle actin and beclin 1. Group II showed macrovesicular and microvesicular steatosis, a strong positive immunoreaction of αSMA (alpha smooth muscle actin) and a weak positive immunoreaction of beclin 1. Group III showed a much better histological picture and a moderate positive immunoreaction of αSMA and beclin 1. In conclusion, liraglutide could treat NAFLD by improving hepatic steatosis and fibrosis, regulating lipid profile and liver functions, and enhancing autophagy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
